The International Head and Neck Cancer Epidemiology (INHANCE) Consortium reported that tobacco and alcohol use account for a large proportion of cases in Latin America (83%) and Europe (84%) but only 51% of head and neck cancer (HNC) cases in the United States. The population attributable risks for tobacco and alcohol were lower for women (57%) than men (74%), and lower for younger subjects (33%) than older subjects (73%). In recent years, tonsillar and tongue cancer incidence, and oral cavity and pharyngeal cancer incidence in young women have been increasing at alarming rates in the US, which may partly be due to human papillomavirus (HPV) infection. Since it is unlikely that tobacco, alcohol and HPV account for all HNC cases, other risk factors must continue to be investigated. Furthermore, cancer risk prediction models may aid in personalized prevention strategies targeted to high risk populations such as young HPV positive individuals and individuals with family history of HNC. We propose to develop HNC risk prediction models within the INHANCE Consortium database of 18,000 cases and 28,000 controls from 27 studies.
Our specific aims are: 1) to conduct a comprehensive analysis of risk factors by pooling additional data on occupational exposures and oral hygiene, and to estimate their corresponding attributable risks by geographic region in the INHANCE Consortium;2) to develop the first risk prediction models for HNC and for oral cavity, oropharyngeal, hypopharyngeal, and laryngeal cancer for the US, using aim 1 results and baseline cancer hazard rates derived from SEER data;and 3) to validate the HNC risk prediction model in US cohorts from the Cohort Consortium. Competing risk models will be used to estimate the probability of developing these cancers over a 5-, 10-, and 20-year time interval. The risk factors under investigation will include tobacco smoking, alcohol drinking, family history of HNC, HPV infection, select genetic variants, involuntary smoking, sexual behaviors, oral hygiene, dietary factors, physical activity, socioeconomic status, occupational exposures, and BMI. We will validate the prediction models by comparing the expected and observed number of cancer cases, and ROC curves using cohort data from the Cohort Consortium. Our HNC risk prediction models will have the potential for: 1) clinical use within the context of personalized medicine in the future, 2) for dentists in decision making on whether to proceed with oral cancer exams beyond conventional visualization examination, 3) for public use by individuals interested in understanding their HNC risk (ie, individuals who have family history of HNC), and 4) for research use to select high risk populations for studies of primary prevention. Additionally, the prediction model can serve as a tool to estimate risk reduction for individuals to evaluate the impact of behavior modification (i.e., quitting cigarette smoking or reducing alcohol drinking). The large collaboration of multidisciplinary investigators in the INHANCE Consortium provides an exceptional opportunity for this project on comprehensive risk factor evaluation and risk prediction models for HNC.

Public Health Relevance

Our project on the development of head and neck cancer risk prediction model is important for public health because it will contribute as a tool to predict the absolute risk of head and neck cancer across various age groups and risk factor profiles. This project will be the first of its kind to estimate the attributable risks of a comprehensive list of head and neck cancer risk factors across world regions (North America, Latin America, Europe, and East Asia), to utilize a large pooled data in the international head and neck cancer consortium for risk prediction model for oral cavity, oropharynx, hypopharynx, and larynx in the US, and to validate the risk prediction model in the US cohorts within the Cohort Consortium. Head and neck cancer risk prediction is essential to facilitate personalized health care in clinical and intervention settings in order to reduce head and neck cancer incidence and to improve survival.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA158848-01A1
Application #
8242482
Study Section
Epidemiology of Cancer Study Section (EPIC)
Program Officer
Verma, Mukesh
Project Start
2012-03-01
Project End
2014-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
1
Fiscal Year
2012
Total Cost
$162,581
Indirect Cost
$53,831
Name
University of Utah
Department
Family Medicine
Type
Schools of Medicine
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112